139243-55-3

Basic information

• Product Name: Butanoic acid, 3-aMino-, Methyl ester, hydrochloride, (3S)-
• Synonyms: Butanoic acid, 3-aMino-, Methyl ester, hydrochloride, (3S)-;(S)-Methyl 3-aminobutanoate hydrochloride;(S)-METHYL-HOMO-BETA-ALANINATE HYDROCHLORIDE;METHYL(S)-HOMO-BETA-ALANINATE HYDROCHLRIDE;S-3-amino-Butanoic acid methyl ester hydrochloride;METHYL (S)-HOMO-BETA-ALANINATE HCL
• CAS NO: 139243-55-3
• Molecular Formula: C₅H₁₁NO₂*ClH
• Molecular Weight: 153.60728
• Mol File: 139243-55-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Butanoic acid, 3-aMino-, Methyl ester, hydrochloride, (3S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 3-aMino-, Methyl ester, hydrochloride, (3S)-(139243-55-3)
• EPA Substance Registry System: Butanoic acid, 3-aMino-, Methyl ester, hydrochloride, (3S)-(139243-55-3)

Safety Data

• Hazardous Substances Data: 139243-55-3(Hazardous Substances Data)

Usage

General Description

The chemical "Butanoic acid, 3-amino-, methyl ester, hydrochloride, (3S)-" is a compound that consists of butanoic acid, an amino group, and a methyl ester, all of which are bound to a hydrochloride group. The compound is in the (3S)- configuration, meaning that the stereochemistry of the molecule is specifically oriented in a certain way. This chemical may have various applications in pharmaceuticals, agriculture, and chemical synthesis, and its specific properties and functions depend on the arrangement of its constituent structures.

Upstream product

• 75-77-4 chloro-trimethyl-silane 
• 3775-72-2 L-3-aminobutyric acid 
• 67-56-1 methanol 
• 137132-12-8 (3RS)-3-aminobutanoic acid methyl ester hydrochloride 
• 108-59-8 malonic acid dimethyl ester 
• 158851-30-0 (S)-3-tert-butoxycarbonylaminobutyric acid 
• 113034-32-5 methyl ester of (S)-3-(benzoylamino)butanoic acid 
• 106539-14-4 (S)-methyl 3-(tert-butyloxycarbonylamino)butyrate 

Downstream Products

• 1219839-41-4 C₁₂H₂₁NO₅ 
• 147034-51-3 (S)-3-Amino-N-methyl-butyramide 

Relevant articles and documents

Stabilization of β-peptide helices by direct attachment of trifluoromethyl groups to peptide backbones

The 14-helix structure of oligo-β-peptides was significantly stabilized by direct attachment of CF3 groups to their backbones. Our studies indicate that this stabilization originates from the CF 3-promoted increase in the intramolecular hydrogen-bonding ability of their backbone amides, leading to a novel strategy to stabilize peptide folding.

An extension of the 'Bip method': Induced axial chirality in a series of dipeptides based on Bip/β2,2-HBip combined with Ala/β3-HAla

In the search for an extension of the 'Bip method' for determining the absolute configuration of β-amino acids and β-peptides, dipeptides based on β2,2-HBip/l(d)-Ala, Bip/l-β3-HAla, and β2,2-HBip/l-β3-HAla were synthesized in solution and the induced circular dichroism (ICD) in their biphenyl core evaluated in comparison with the previously investigated Bip/l(d)-Ala series. Weak, poorly informative ICDs were observed in MeOH solution for the linear N-Boc protected dipeptide methyl esters based on β2,2-HBip, as well as for those with Ala/β3-HAla at the N-terminus of Bip/β2,2- HBip. However, a significant ICD was recorded for Boc-Bip-l-β3- HAla-OMe. These results were confirmed by low-temperature 1H NMR spectroscopy studies of the dipeptides in CDCl3 and CD3OD solutions, showing two diastereoisomeric conformers in significantly different populations for Boc-Bip-l-β3-HAla-OMe in CD3OD. In general, ICDs were found to be weaker for dipeptides containing β-amino acids as compared to those of their α-amino acid counterparts.

Aryl imidazole derivative and application thereof

The invention relates to an aryl imidazole derivative and application thereof. The aryl imidazole derivative is a compound shown as a formula (I) in the description or pharmaceutically acceptable salt thereof. The invention also discloses application of the aryl imidazole derivative in preparation of drugs for treating cancers. The invention further discloses application of the aryl imidazole derivative in preparation of drugs for treating diseases caused by EGFR mutation.